The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines the importance of continued research to develop novel therapeutics for this disorder. This can only be accomplished with successful translation of basic science discoveries into direct human application through effective clinical trial design and execution that results in a substantially improved clinical course and outcomes. In this respect, phase II clinical trials play a pivotal role in determining which of the multitude of potential basic science discoveries should move to the large and expansive registration trials in humans. A critical examination of the phase II trials in heart failure reveals multiple shortcomings in their concept, design, execution, and interpretation. To further a dialogue on the challenges and potential for improvement and the role of phase II trials in patients with heart failure, the Food and Drug Administration facilitated a meeting on October 17, 2016, represented by clinicians, researchers, industry members, and regulators. This document summarizes the discussion from this meeting and provides key recommendations for future directions.
Objectives: Myocardial perfusion imaging (MPI) with positron emission tomography (PET) has advantages over single-photon emission computerized tomography, particularly for women. This investigation was undertaken to define the prognosis of a normal stress PET MPI study in women. Methods:The cohort comprised 457 women evaluated for suspected coronary artery disease (CAD) who had normal pharmacologic stress 82Rb PET MPI. No patient had clinically evident CAD. Kaplan-Meier estimates were used to determine death and initial nonfatal cardiac event rates over 7 years. Log rank tests were used to assess the relationship between baseline cardiac risk and events during follow-up, and to contrast survival in the cohort with age- and gender-matched US census comparators. Results: During follow-up, there were 11 deaths (all nonischemic), 3 nonfatal myocardial infarctions, 3 percutaneous coronary interventions and 1 coronary artery bypass operation. Average risks of death and initial nonfatal cardiac events were 0.72 and 0.47% per year, respectively. Cardiac events were associated with a history of diabetes (p < 0.0003) and a family history of CAD (p < 0.05). Conclusion: A normal cardiac PET study is associated with a very low rate of future cardiac events. Women with diabetes and a strong family history of CAD are more likely to sustain events and require close surveillance for the development of coronary disease.
Introduction and Aims: Diabetes is a well-recognized risk factor for chronic kidney disease (CKD) and the co-occurrence of CKD in diabetes confers an even higher risk of poor cardiovascular outcomes. Guidelines recommend renin-angiotensin-aldosterone (RAAS) inhibitors to slow the progression of diabetic kidney disease (DKD), however patients with DKD are at high risk for hyperkalemia, which may limit or prevent RAAS inhibitor use. Currently available potassium (K+)-binding agents for hyperkalemia treatment are generally poorly tolerated, which may limit long-term use. AMETHYST-DN evaluated the novel agent patiromer, the active moiety of which is a nonabsorbed potassium (K+)-binder, in a 1-yr trial of patients with diabetes and CKD on RAAS inhibitors. In this post hoc subanalysis, we report the results of long-term patiromer therapy in patients with advanced CKD (stages 4-5).
Introduction and Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi), such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are preferred first-line drugs in high-risk patients (pts) with diabetes. Dual therapy (D) with an ACE inhibitor and an ARB, or combined therapy in which an ACE and/or ARB is used with a mineralocorticoid antagonist (C), may have greater cardiorenal benefit versus monotherapy in select patients with DKD, and in patients with heart failure. However, the use of D or C RAASi therapy is frequently limited by hyperkalemia (HK).